Background Flow cytometry has been used in many different settings to, for example, analyse subpopulations of leucocytes in quality control of stem cell grafts and in the diagnosis of lymphoma and leukaemia. In transfusion medicine, it has mainly been utilized for detection and semiquantification of various blood group antigens as a complement to traditional serology, for quality control of blood components and detection of fetomaternal haemorrhage. Today, when flow cytometers are becoming smaller, cheaper and more user friendly and are available in many routine laboratories, the method should be considered as a valuable tool to use in addition to serology and genomic typing.
Introduction
Flow cytometry is a technique utilized in many different settings, both in the routine laboratory and in research facilities. Many types of material can be tested, for example cells, DNA and bacteria. Through the years flow cytometry has been used to examine RBCs in different immunohaematology settings [1] [2] [3] , although it has never completely found its way into the routine transfusion medicine laboratories as detection of normal expression of blood group antigens is readily and quickly performed with traditional serological methods. Today, the main use of flow cytometric analysis in transfusion medicine is for quality control of blood components (leucocyte counts), detection of fetomaternal haemorrhage, elucidating aberrant antigen expression, for red blood cell (RBC) phenotyping in the reference laboratory setting and analysis of platelets. When analysing RBCs by flow cytometry there are methodological considerations to take into account, for example avoiding agglutination. Different methods used for staining and analysis of RBCs used by immunohaematology laboratories as well as in a research was very nicely reviewed by Arndt & Garratty [4] .
Cellular therapies are part of the transfusion medicine laboratories in many places, and flow cytometry is widely used in the haematopoietic stem cell transplantation (HSCT) setting. The most important analysis is to define content of CD34-positive haematopoietic progenitor cells in stem cell grafts [5] and to measure T-cell content prior to allogeneic transplantations. Guidelines are issued by JACIE (Joint Accreditation Committee-ISCT & EBMT). More recently, the possibility to perform an ex vivo T-cell depletion prior to transplantation has made it possible to use haploidentical donors for some patient groups. This has made analysis of recipient and donors samples more complex and put a demand on flow cytometry laboratories to develop gating strategies and stringent analysis. As this is a field in its own right, analysis in the HSCT setting will not be discussed further.
The first clinical flow cytometers came into use in the 1970s and enabled the measurement of different characteristics of single cells (or particles) by streaming them in a 'sheath' fluid past a laser light source. Briefly, light scattering (FSC, forward scatter and SSC, side scatter) can distinguish cells of different size and granularity. When cells labelled with fluorochrome-conjugated antibodies pass the laser, the fluorochrome is excited and emits light of a different wavelength. The light is sent to different detectors known as photo multiplier tubes (PMTs) by the use of optical filters and reflectors. The electrical pulses originating from the light signal detected by the PMTs are then processed and each event can be plotted on a graphical scale, and dot plots or histograms can be used to visualize the results.
The following is an overview on how analysis by flow cytometry can be used within the field of transfusion medicine.
Detection and semiquantification of erythrocyte antigens
Flow cytometry has been used to examine erythrocyte antigens for many years and is considered as a very good complement when aberrant expression of various antigens needs to be elucidated. Many research groups have included testing by flow cytometry in discovery of new variants of blood group antigens and also to verify new blood group systems [6] [7] [8] [9] [10] [11] . The use of flow cytometry for analysis of (glyco)protein blood group antigens/systems will be very briefly touched upon and exemplified by RHD and KEL where many different antibodies directed to specific epitopes are used in combination to examine the expressed protein.
At the clinical Nordic Reference Laboratory for Genomic Blood Group Typing and at the transfusion medicine research laboratory at Lund University we use flow cytometry frequently to evaluate and examine antigens within different carbohydrate blood group systems, for example ABO, P1PK, GLOB and FORS [6, [12] [13] [14] [15] . Flow cytometry was also included when the genetic background of the VEL blood group system was elucidated [7, 16] .
Investigation of RhD expression
Flow cytometry is primarily used to evaluate D antigen expression and antigen site density in D variants. Analysis of samples carrying partial D expression and more commonly, D weak samples is complex and is a task that takes significant thought and consideration prior to testing. There are many monoclonal anti-D that have been evaluated by monoclonal antibody workshops for use in flow cytometry, and there are also comments on techniques used for staining and how to evaluate antigen density [17, 18] . In a study by Wagner et al. [19] , they very nicely present the examination of D weak alleles where flow cytometry was part of the investigation, and in total more than 50 anti-D reagents were used. Others have also characterized new RHD alleles and correlated genotype with phenotype [20, 21] . Silvy et al. [22] used epitope mapping of different D variants by flow cytometry with workshop-verified reagents.
Kell
Thirty-six different blood group antigens have been described on the Kell glycoprotein. Various antibodies to specific antigens, as well as anti-CD238, an antibody towards the complete glycoprotein, have been used for elucidating weak expression, new antigens and K O phenotypes. Velliquette et al. [23] used flow cytometry in the elucidation of high-prevalence antigens in the Kell blood group system. In a Dutch study, Ji et al. [24] examined a large cohort of donors for antigen variants in the Kell blood group system. They also included samples from individuals with a K 0 phenotype and a sample from an individual with McLeod syndrome, in which Kell antigens are weakly expressed. In a Brazilian study, three K 0 samples were confirmed by flow cytometry to be KÀ, kÀKp (aÀbÀ), JsbÀ [25] .
ABO expression and flow cytometry
For ABO, flow cytometry has previously been used for a variety of purposes: (1) to try (pregenomic testing) to define homo and heterozygosity for alleles exhibiting normal amounts of ABH antigens [26] ; (2) to examine if alterations of ABH antigens occur during storage in the blood bank [27] ; (3) to analyse the decrease of ABH antigen levels in leukaemia patients. It was reported that both loss of A and B antigens could be detected, as well as a decrease in H antigen levels [28] . The problem encountered in these reports is that the sensitivity of the assay appeared to be quite low. Many of the studies did not include weak control RBCs and in the two studies where they did include A x RBCs they were unable to detect any A antigen on these RBCs at all [26, 28] .
In a previous study, we devised a method for detection of A and B antigen with flow cytometry optimized to detect very small amounts of antigen on RBCs, remaining after treatment with a family of newly discovered exoglycosidases from bacteria [29] . A large number of different ABO reagents were screened and tested with a variety of secondary antibodies to find the optimal settings. This method has also been validated for detection of weak expression in genetically defined A and B subgroups and is now in clinical use for resolving ABO discrepancies [12, 13] .
ABO discrepancies
As we at the Nordic Reference Laboratory for Genomic Blood Group Typing encounter many samples with aberrant ABO expression we have been able to correlate expression to genetically defined background [12] , which has shown a remarkable reproducibility from sample to sample. Some ABO subgroups are very distinct and just by analysing the histogram and dot plot the genetic background can be predicted with accuracy, for example the A finn phenotype. In addition, flow cytometry has been used for discrepancies of Bombay and para-Bombay samples and investigation into samples with weakened expression due to either pregnancy or haematological malignancy. The combination of serology, flow cytometry and genetic testing gives a very thorough and complete picture of ABO variants and defined subgroups.
Two examples are given here where flow cytometry has been useful in the elucidation of intriguing ABO discrepancies and where genetic testing could be correlated to the results.
(1) The most common ABO subtype in northern Europe is the A 3 phenotype. A 3 was already identified in the 1930s [30, 31] , and the mixed field definition of A 3 was characterized by a few large agglutinates among a large number of free unagglutinated RBCs. This was very well corroborated when A 3 samples were tested by flow cytometry. Two populations of cells, group A and group O, were detected but also seen were cells expressing the antigen at an intermediate level (Fig. 1a) and therefore clearly distinguishable from a chimera, where two distinct populations of cells are seen (Fig. 1b) . A mixed field pattern seen in traditional serology could also indicate previous transfusions with nonidentical ABO units and if the transfusion history of the patient is not known it would be difficult to define if it is an ABO subgroup, that is A 3 , or a transfusions related mixed field pattern. By flow cytometry this is possible to achieve. Genetic testing for the A 3 phenotype seen in our population has until recently not been available. The mutation causing the A 3 phenotype is not in the open reading frame of the ABO gene but in a regulatory region of intron 1 [32] . The mutation is found in close proximity to a GATA site approximately 5Á8 kilo base pairs into the intron. Three different mutations were shown to give rise to an A 3 or A 3 -like flow cytometry pattern of which one was by far the most frequent and could be correlated with the original A 3 phenotype reported. (2) In the setting of a minor ABO-incompatible HSCT, where group O donor haematopoietic stem cells are transplanted to a group A recipient we have in our laboratory encountered problems in routine ABO typing. Even though these patients have been defined as complete donor chimeras according to DNA-based short-tandem repeat analysis, that is they should type as group O, aberrant ABO expression in forward typing was detected. The question then arising was whether this was due to reoccurrence of RBCs derived from a recipient-specific erythroid progenitor which may indicate relapse or something else. In a recently published paper [33] , we showed that the reaction seen is not a true mixed field reaction which would indicate relapse but a low level expression of ABO antigen on all RBCs in the sample (Fig. 1c) . The expression was shown to be due to A/B antigen adsorption of type 1 glycolipids from plasma (derived from nonhaematopoietic cells) in secretor individuals and in these cases rejection of the HSCT could be ruled out.
Detection of mixed field reactions and minor cell populations
Flow cytometry is very well suited to detect small populations of cells which are a feature routinely used for posttreatment follow-up of leukaemia and lymphoma, that is minimal residual disease analysis and for HLA-based chimerism analysis post-haploidentical HSCT. The mixed field reactions in ABO and RhD routine typing which are encountered from time to time in the transfusion medicine laboratory may be due to several things of which previous transfusions of nonidentical ABO and/or RhD blood units are the most common. When previous transfusions have been ruled out the mixed field reaction may be caused by; congenital chimerism; fetomaternal haemorrhage in the case of pregnancy; an ABO subgroup phenotype with a typical mixed field reaction as, for example A 3 ; and non blood group identical HSCT.
Chimerism
Chimerism as a cause of blood group typing discrepancies has been known for a long time, and there are several reports of case studies [34, 35] , and it has also been reviewed by Drexler et al. [36] and Bluth et al. [37] . A congenital chimeric state is present when two or more distinct cell populations containing genetic material from more than one zygote exist within an individual. From a transfusion medicine point of view, it is important to solve ABO discrepancies especially for blood donors to ensure safe transfusions for patients. If a potential blood donor is found to be chimeric it is recommended that he or she does not donate blood, whereas if the typing discrepancy is due to a genetically defined ABO subgroup the donor can donate. In the work up of cases like this flow cytometry will very clearly show if there are two distinct populations present.
Fetomaternal haemorrhage
Fetomaternal haemorrhage (FMH) is defined as loss of foetal cells into the maternal circulation. To accurately detect and quantify, FMH is essential in the setting of obstetric management of alloimmunization in RhD-negative women. The volume of foetal blood is used to calculate the correct dosage of prophylactic anti-D (RhIg) to be distributed to avoid alloimmunization against RBCs from an RhD-positive foetus.
Different methods have been applied to identify foetal cells [38] , but the Kleihauer-Betke test has probably been the one most commonly used. The test was published in 1957 [39] and is based on the resistance of HbF to acid elution: RBCs containing HbF are stained, whereas adult RBCs are not. This method can be appropriate for screening for FMH but is subjective and the reproducibility can be poor. When it comes to dose determination of RhIg to be given the Kleihauer-Betke test is semiquantitative, and calculations may result in an incorrect dose of RhIg to be given [40] .
One of the first reports about using anti-D (polyclonal, unconjugated with a fluorochrome-conjugated secondary antibody) to detect foetal cells in maternal circulation in a flow cytometry setting was published in 1984 by Medearis et al. [41] where they also suggested that flow cytometry analysis could be used for postpartum screening to determine which patients would require RhIg. In 1989, Nance et al. [42] presented a method using anti-D for detection of foetal RBCs, and they concluded several advantages of flow cytometry in comparison with traditional methods. Bayliss et al. [43] compared five different methods used to detect foetal cells and concluded flow cytometry to provide objectivity and reproducibility to the testing. Further on methods describing testing with monoclonal fluorochrome-conjugated anti-D were published [44] [45] [46] and a in comparison between methods, Bromilow et al. [47] concluded that testing by flow cytometry with a fluorochrome-conjugated antibody was superior to other methods.
In 1994, Thorpe et al. [48] described a flow cytometry method to detect different types of haemoglobin in RBCs by intracellular staining. The use of anti-HbF to distinguish between foetal and maternal RBCs has both advantages and disadvantages. It can be used regardless of blood group, but maternal RBCs may contain a minor percentage of HbF, which may cause problems when it comes to clearly define foetal and maternal cell populations [49] . In addition, when testing samples from mothers with haemoglobinopathies this must be taken into account when evaluating the result.
Several groups have proposed the use of anti-HbF for identification of foetal cells [50, 51] in different settings, used by itself [49] or in combination with anti-D [52] . Anti-HbF is also used in combination with an antibody towards carbonic anhydrase (CA), an enzyme that is fully expressed only after birth and hence all cells positive for CA are derived from the mother and maternal cells containing HbF can be distinguished from foetal cells [53] .
Taken together there is a consensus that the use of flow cytometry testing has several advantages to the traditional methods in terms of accurate detection and quantification. There are several kits available on the market for foetal cell count and how to choose kit or perhaps inhouse combination of antibodies is up to the discretion of each laboratory.
Quality control of blood components
Flow cytometry is one of the methods used to evaluate residual leucocytes in leucodepleted blood components. International and national guidelines are issued [54, 55] and the requirements according to European and Swedish guidelines (http://www.kitm.se/sv/handboken) are that 90% of blood components should contain less than 1 9 10 6 leucocytes/unit (for details see Guide to the preparation, use and quality assurance of blood components 19th edition, European Committee on Blood Transfusion). The use of flow cytometry for quality assurance purposes in this setting was proposed and tested in the late 1980s and early 1990s [56] [57] [58] and have been used in many laboratories. Both in-house methods and commercial kits have been used to enumerate residual white blood cells in blood components used for transfusion [59, 60] . Flow cytometry is now widely used for this application, but it has been emphasized that optimization of the instrument and standardization of gating strategies is important to avoid intra and interlaboratory variation [59] [60] [61] .
Platelets

Human Platelet Antigens
To date, there are 35 Human Platelet Antigens (HPA) reported, and they reside on six different glycoproteins (GP) of which the majority are expressed on the GPIIb/IIIa complex (http://www.ebi.ac.uk/ipd/hpa/table1.html). Due to lack of serological reagents, HPA phenotyping by flow cytometry can only be performed for HPA-1a, and hence, genotyping is the preferred method for HPA typing. Anti-HPA-1a is clinically a very important platelet antibody and is implicated in around 80% of cases with foetal and neonatal alloimmune thrombocytopenia in Caucasians [62] . In a transfusion medicine setting, it is essential to have a donor cohort defined as HPA-1a-and this can easily be achieved by flow cytometry screening. In a Caucasian population, the expected frequency to be HPA-1a negative is approximately 2% [63] . HPA-1a phenotyping can easily be performed by flow cytometry using FITC-conjugated anti-HPA-1a (BeckmanCoulter, clone SZ21). Kjaer Killie et al. [64] showed that to reduce the number of samples to be tested, screening can be performed on either platelet rich plasma or platelet concentrates produced from pools of four buffy coats in a simple, high-throughput fashion.
Platelet cross-match
From time to time, transfusion services encounter patients with platelet refractoriness which manifests as poor response to platelet transfusions. This may be due to alloantibodies to either human leucocyte antigens (HLA) or more rarely HPA [65] . To manage these patients, several centres select platelet concentrates from HLA class I-matched blood donors. Other centres have used flow cytometry-based platelet cross-match as an alternative strategy to identify platelets units in the blood bank's platelet inventory that were likely to give an adequate posttransfusion platelet count increment [66, 67] . After introduction of Luminex-based assays of determining the fine specificity of HLA and HPA antibodies it is now possible to select compatible platelets donors who lack the HLA and/or HPA antigens.
Platelets during storage
Collection and storage of platelets inevitably result in morphological and biochemical changes also known as the platelet storage lesion [68] [69] [70] . Several flow cytometry-based assays have been used to evaluate storage lesions but have not gained wide acceptance for routine use as a quality control measure. Among the activation markers that have been tested by flow cytometry are expression of CD42b, CD62P as well as binding of AnnexinV, PAC-1, antifibrinogen [71] [72] [73] of which CD62P (P-selectin) is probably the most frequently used. It is often useful to determine the level of platelet activation both before and after addition of thrombin receptoractivating peptides, TRAP [71] . Where changes in platelet collection procedures or storage medium have occurred, flow cytometry has been a used in several studies to assess the impact of the changed procedure [73, 74] .
Conclusion
Today, when flow cytometers are becoming smaller, cheaper and more user friendly and are available in many routine laboratories, the method should be considered as a valuable tool to use in addition to serology and genomic typing. With that in mind it is important to give thought on how to set-up experiments, assure that accurate settings are used and that the compensation is performed correctly.
Flow cytometry is today used in both routine and research laboratories and has been shown to help in investigations of patient samples and to be an important addition in research focused studies.
